Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2001

View Archived Issues

Inflazyme and Helicon to study drug leads related to learning and memory

Bristol-Myers Squibb to conduct Glucovance trial in pediatric type 2 diabetes

Telik and Sanwa Kagaku extend drug discovery alliance for second time

Genome Therapeutics to identify DNA map of pathogenic organism for Wyeth Lederle Vaccines

Aviron highlights Q4 and year-end 2000 developments

Repligen updates product development programs

University of Iowa licenses AAV technology to Targeted Genetics

Schering-Plough identifies novel antifungal agents that damage the fungal cell wall

Curvularol: a naturally produced cell cycle inhibitor

In vitro study provides support for development of CS-891 as Rx for alopecia

Novel vaccine approach warrants further evaluation in pancreatic cancer

Genta licenses antisense technology to Atugen

Abgenix and Celltech enter license and codevelopment agreement based on SLAM technology

Candidate AGE formation inhibitor exhibits renoprotective effects in diabetic rats

Lundbeck buys out Byk Gulden in German joint venture

Demegen to expand cancer research

SCIO-469 now being studied in phase Ib trial for treatment of RA

Clinical data on BMS-232632 presented at Chicago conference

Durect setting fast pace in phase II DUROS sufentanil trial for chronic pain

Avax subsidiary to evaluate TK suicide gene therapy technology

Phase III trial of irofulven in pancreatic cancer proceeds on schedule

BCH-10618 shows favorable resistance profile in cell culture experiments

Preclinical studies point to role for ACH-126443 in combination anti-HIV therapy

Ivax acquires Lilly's talampanel, an advanced-stage antiepileptic

Selective Y1 receptor antagonists and their use described by BMS

Antiviral agents designed at Biota are reportedly superior to pirodavir

Recent patent covers new antibacterial quinoline derivatives

Former SmithKline Beecham provides macrophage scavenger receptor antagonists

ISIS-28030: a new antisense inhibitor of PI3K p85

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...